What's Stirring with Select Medical?
Folks, here's some rumbling in the healthcare sector that's got my attention. Seems like Select Medical Holdings Corporation, trading under NYSE:SEM, is facing heat over a proposed sale price. We're looking at a $16.50 per share buyout galore, and it ain't sitting well with everyone. Turns out, Bleichmar Fonti & Auld LLP is poking around. Why? They smell something fishy about how this whole deal went down.
The Breakdown of the Buyout
Let's chew on this: Back in March, Select Medical let the world in on a deal—a buyout by a consortium. At the head of that pack? Robert A. Ortenzio, Select's co-founder, and a few other big fish. They're rolling out with Welsh, Carson, Anderson & Stowe, a private equity firm that's no stranger to Select's inner circle. The $16.50 per share proposition is on the table, and stockholders are expected to just nod along.
What's the Big Deal with $16.50?
Now, $16.50 might look smooth, but here's the rub: folks like Ortenzio and his posse get to 'rollover' their shares into the new company. Public stockholders? Tough luck, no rollover for them. This selective candy store access ain't winning over the masses.
"Is this really a fair shake for everyone involved?" You might ask. That's precisely what Bleichmar Fonti & Auld LLP intends to find out.
Shareholder Vote and Its Implications
June 26, 2026, that's the D-Day for rounding up shareholders. Until then, this watchful lawyer's eye is peeled on whether Select Medical insiders danced a little too close during this merger waltz. The special committee's nodding approval adds to the intrigue. But hey, approving ain’t the same as wishing for transparency, right?
Legal Eagles on the Prowl
So here's the lowdown. If you’ve got Select Medical stock burning a hole in your pocket, you might want to chime into this circus. Bleichmar Fonti & Auld LLP promises a gander into whether the directors played nice. And hey, they’re saying lawsuits via their avenues won’t cost you—seats still open for those willing to step up.
What's in It for Investors?
Alright, stepping back from the cliff for a second here. If you're holding NYSE:SEM, this probe could throw a spanner in Select Medical's works heading into the merger day's close. With BFA promising courtroom wrangling at no extra shareholder cost, it seems they mean business. They’ve got a track record backing them up, with a string of heavyweight legal victories under their belt.
Final Thoughts
So, investors, sit tight and keep those eyes peeled. This situation's like watching a chess game play out, but the stakes are real money. Whether this deal proves an ill fit or a smooth sail into profitability, these corporate dynamics ain't for the faint of heart. Keep your ear to the ground, folks— who knows what'll unfold next.
